QuantRx(R) Announces FDA 510(k) Clearance For Its RapidSense(R) Methamphetamine Test
QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its RapidSense drugs-of-abuse (DOA) Methamphetamine test. The RapidSense Methamphetamine test is the first of QuantRx’ DOA tests based solely on its proprietary technology approved by the FDA.
More: continued here